Showing results (211-220 of 523) with videos related to
Sort By:
Pageof 53
Future Oncology (London, England)|March 6, 2024
Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancerSabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, et al.Current Pharmaceutical Design|October 22, 2013
Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'Sara Pilotto, Maria Bonomi, Francesco Massari, et al.Cancer|June 29, 2004
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinomaMichele Milella, Alain Gelibter, Serena Di Cosimo, et al.Anti-Cancer Drugs|February 12, 2009
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicityCecilia Nisticò, Emilio Bria, Vanja Vaccaro, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 2, 2019
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Matteo Brunelli, et al.Acta Bio-Medica : Atenei Parmensis|January 25, 2022
An unusual approach for a cervical mass: sternotomy for the treatment of a giant cervico-thoracic lipomaGerardo Petruzzi, Lucrezia Trozzi, Silvia Moretto, et al.Clinical Lung Cancer|July 22, 2023
Non-Small Cell Lung Cancer With N1 Involvement or Skip Metastases Presents the Same Survival Outcome: Results From a Multicentric StudyMarco Chiappetta, Carolina Sassorossi, Filippo Lococo, et al.The Oncologist|March 13, 2020
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?Alice Avancini, Giulia Sartori, Anastasios Gkountakos, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 15, 2008
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II studyAlessandra Fabi, Mariangela Ciccarese, Giulio Metro, et al.Journal of Experimental & Clinical Cancer Research : CR|May 10, 2011
Maintenance therapy in NSCLC: why? To whom? Which agent?Silvia Novello, Michele Milella, Marcello Tiseo, et al.Pageof 53